Results of a phase II clinical trial conducted at MD Anderson Cancer Center revealed combination targeted therapy, consisting of rituximab, lenalidomide, and ibrutinib, had an 84.6% overall response rate and 38.5% complete response rate when given prior to any chemotherapy for newly diagnosed patients with a specific type of diffuse large B-cell lymphoma.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
